Beam Therapeutics (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model.
Engraftment is the process under which transplanted stem cells enter the bloodstream, reach the bone marrow, and produce new blood cells.
The data also showed the inducement of "robust, durable production of fetal hemoglobin," the company said.
Beam Therapeutics said its platform uses two investigational drug products to provide a non-genotoxic alternative to traditional transplant medicines: the BEAM-103 antibody and the BEAM-104 cell therapy. The company plans to advance the two candidates in sickle cell disease and beta-thalassemia, which are blood disorders.
BEAM-103 dosing was well tolerated, with no need for antibiotics or additional supportive care, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。